Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026)
Nuvectis Pharma (NVCT) reported Return on Capital Employed of 162.68% for Q1 2026, down 2424.0% on a YoY basis from 7.0% in Q1 2025, and down 20.07% sequentially from 135.49% in Q4 2025.
Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 5 years of Return on Capital Employed data on file, last reported at 162.68% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 2424.0% year-over-year to 162.68%; the trailing twelve-month figure through Mar 2026 stood at 162.68% (down 2424.0% YoY), and the FY2025 full-year result was 232.46%, down 3403.0% from the prior year.
- Return on Capital Employed declined to 162.68% in Q1 2026, from 135.49% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 97.75% in Q3 2022 to a low of 218.99% in Q4 2024.
- A 5-year average of 146.66% and a median of 141.49% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 5234 bps in 2024 and surged 8350 bps in 2025, its largest moves.
- Tracing NVCT's Return on Capital Employed over 5 years: stood at 116.93% in 2022, then slumped by 43 bps to 166.65% in 2023, then sank by 31 bps to 218.99% in 2024, then surged by 38 bps to 135.49% in 2025, then retreated by 20 bps to 162.68% in 2026.
- Business Quant data shows NVCT's Return on Capital Employed at 162.68% in Q1 2026, 135.49% in Q4 2025, and 133.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Nuvectis Pharma | 453.54 Mn | 453.54 Mn | - | -162.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -162.68% |
| Dec 31, 2025 | -135.49% |
| Sep 30, 2025 | -133.90% |
| Jun 30, 2025 | -124.55% |
| Mar 31, 2025 | -138.43% |
| Dec 31, 2024 | -218.99% |
| Sep 30, 2024 | -176.42% |
| Jun 30, 2024 | -166.69% |
| Mar 31, 2024 | -168.58% |
| Dec 31, 2023 | -166.65% |
| Sep 30, 2023 | -126.54% |
| Jun 30, 2023 | -141.49% |
| Mar 31, 2023 | -141.87% |
| Dec 31, 2022 | -116.93% |
| Sep 30, 2022 | -97.75% |
| Jun 30, 2022 | -101.98% |
| Mar 31, 2022 | -174.21% |